Skip to main content
    C

    Cardiff Oncology Inc (CRDF)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.85
    -0.00 (-0.15%)

    Market Cap: $65.95M

    Last updated: Nov 17, 2026 at 4:39 PM ET

    Cardiff Oncology Inc (CRDF) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Cardiff Oncology (CRDF) trades at 115.3x sales and 2.3x book value. Its P/S of 115.3x is below its 5-year median of 200.5x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/EN/A
    Price to sales115.3x
    Price to book2.3x
    PEGN/A
    FCF yield-61.9%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/S is 30.7% below 166.4x and its P/B is 15.0% above 2.0x.

    MultipleCurrent5-year median10-year median
    P/S115.3x200.5x166.4x
    P/B2.3x2.0x2.0x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 117 to 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/S ranged from 11.8x in 2018 to 866.8x in 2020.

    Year endPriceP/SP/B
    2025$2.81316.2x4.1x
    2024$4.34291.4x2.5x
    2023$1.48135.5x0.9x
    2022$1.40158.7x0.6x
    2021$6.01657.4x1.7x
    2020$17.99866.8x3.3x
    2019$1.2429.6x1.4x
    2018$3.1511.8x1.2x
    2017$22.1421.4x1.9x
    2016$151.23166.0x3.3x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    Frequently Asked Questions About CRDF

    What is CRDF's price to sales ratio?

    Cardiff Oncology has a price to sales ratio of 115.3x.